Kiniksa Pharmaceuticals International, plc
KNSA
$19.31
$0.663.54%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 9.20% | 3.30% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.20% | 3.30% | |||
| Cost of Revenue | 33.73% | 16.72% | |||
| Gross Profit | -10.11% | -5.27% | |||
| SG&A Expenses | -12.64% | 9.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.38% | 12.07% | |||
| Operating Income | -99.82% | -8,154.70% | |||
| Income Before Tax | -135.79% | -412.54% | |||
| Income Tax Expenses | -247.32% | -11.59% | |||
| Earnings from Continuing Operations | 29.98% | -224.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 29.98% | -224.80% | |||
| EBIT | -99.82% | -8,154.70% | |||
| EBITDA | -104.11% | -3,058.15% | |||
| EPS Basic | 30.56% | -221.82% | |||
| Normalized Basic EPS | -133.97% | -408.87% | |||
| EPS Diluted | 30.56% | -195.00% | |||
| Normalized Diluted EPS | -133.97% | -408.87% | |||
| Average Basic Shares Outstanding | 0.83% | 1.02% | |||
| Average Diluted Shares Outstanding | 0.83% | 1.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
